US-based private equity firm Egyptian American Enterprise Fund (EAEF) has acquired 46.5% stake in Egyptian ophthalmic pharmaceutical products developer Orchidia Pharmaceutical Industries for EGP700m ($39.59m).
EAEF has acquired 38% stake from SPE Capital (formerly Swicorp Private Equity), 3% from Orchidia Ossama Abbass and the rest through a capital increase.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
“EAEF has acquired 38% stake from SPE Capital (formerly Swicorp Private Equity), 3% from Orchidia Ossama Abbass and the rest through a capital increase.”
US-based pharmaceutical company Valeant Pharmaceuticals International plans to divest its stake in female sexual health products developer Sprout Pharmaceuticals.
The divestment will enable the company to streamline its business operations.
